Clinical assessment of the drug Mexol in the treatment of severe traumatic brain injury at the stages of medical care

Author:
V.L. Dyushkevich

Voronezh State Medical Academy. N. N. Burdenko, Voronezh

Place of publication:
Medical alphabet. Emergency medicine 1/22

Summary:
Heddle-brain injury (ChMT) is one of the main reasons for the disability and death of the population. Moreover, mechanical damage to the central nervous system does not tend to decrease in the structure of diseases and injuries. According to WHO, the frequency of craniocre injury annually increases by 2%. In Russia, about 600,000 people receive a traumatic brain injury annually, of which about 50,000 die and the same number of disabled people (Gusev E.I., 2009). Mortality at a severe CMT, according to various estimates, ranges from 10 to 25%, and with the most severe forms reaches 65-70%. In the vast majority of victims (60%), a decrease in performance and disability (epileptic seizures, encephalopathy, paresis and paralysis, speech disorders and other neurological consequences) are observed as a result of injury.